Korro Bio price target lowered to $95 from $105 at RBC Capital

RBC Capital lowered the firm’s price target on Korro Bio (KRRO) to $95 from $105 and keeps an Outperform rating on the shares. The firm notes that dosing for A1AT is on track with first two cohorts of healthy volunteers dosed and no serious adverse events reported to date. While Wave Life Sciences Ltd (WVE) is ahead, Korro is the better way to play RNA editing given unconstrained economics, the analyst tells investors in a research note. RBC adds however that its reduced price target reflects the company’s operating expense.